Astrazeneca Pharma India is reportedly planning to close its Avishkar research and development (R&D) site in Bangalore later this year. The decision is part of the company’s broader global business strategy to simplify its research and development footprint and focus resources on three core therapy areas such as oncology, cardiovascular and metabolic diseases, and respiratory, inflammation and autoimmunity.
The site was working on pharmaceutical development projects and it will no longer carry out early stage research into neglected tropical diseases, TB and malaria.
Astrazeneca Pharma India is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection.
